Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $25.59 to $25.59
• 50-Day Range: $25.55 to $25.59
• 52-Week Range: $9.90 to $25.61
• Volume: 600 shs
• Average Volume: 1.29 million shs
• Market Capitalization: $2.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DCPH Stock Analysis - Frequently Asked Questions

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its quarterly earnings data on Tuesday, February, 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. The company's revenue was up 32.9% on a year-over-year basis.
Read the conference call transcript.

When did Deciphera Pharmaceuticals IPO?

Deciphera Pharmaceuticals (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/06/2024
• Today: 7/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DCPH
• CIK: 1654151
• Web: www.deciphera.com
• Phone: (781) 209-6400
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$194.94 million
• Net Margins: -108.86%
• Pretax Margin: -108.62%
• Return on Equity: -52.42%
• Return on Assets: -40.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.19
• Quick Ratio: 3.94

Sales & Book Value

• Annual Sales: $174.91 million
• Price / Sales: 12.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.38 per share
• Price / Book: 5.84

Miscellaneous

• Outstanding Shares: 86,476,000
• Free Float: 82,438,000
• Market Cap: $2.21 billion
• Optionable: Optionable
• Beta: 0.19